Genetically proxied inhibition of lipid-lowering drug targets and risk of low back pain: A Mendelian randomization study

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Healthcare and Rehabilitation

• Publication date

  2025-10-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.hcr.2025.100053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study

  2023cited by this paper
• Differential Gene Expression Among Patients With Heart Failure Experiencing Pain

  2023cited by this paper
• Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.

  2022cited by this paper
• Impact of dyslipidemia on the severity of symptomatic lumbar spine degeneration: A retrospective clinical study

  2022cited by this paper
• Lipid and metabolic alteration involvement in physiotherapy for chronic nonspecific low back pain

  2022cited by this paper
• Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

  2022cited by this paper
• Discogenic Low Back Pain: Anatomy, Pathophysiology and Treatments of Intervertebral Disc Degeneration

  2022cited by this paper
• Statins Neuromuscular Adverse Effects

  2022cited by this paper
• Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system

  2022cited by this paper
• Circulating omega-6 and omega-3 polyunsaturated fatty acids in painful temporomandibular disorder and low back pain.

  2022cited by this paper
• Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study

  2021cited by this paper
• PCSK9 and inflammation. Maybe a role in autoimmune diseases? Focus on rheumatoid arthritis and systemic lupus erythematosus.

  2021cited by this paper
• The role of PCSK9 in inflammation, immunity, and autoimmune diseases

  2021cited by this paper
• Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement.

  2021cited by this paper
• The Multifaceted Biology of PCSK9

  2021cited by this paper
• Statins and PCSK9 inhibitors: A new lipid-lowering therapy.

  2020cited by this paper
• Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis

  2020cited by this paper
• Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

  2020cited by this paper
• The MR-Base platform supports systematic causal inference across the human phenome

  2018cited by this paper
• Effect of an increased dosage of statins on spinal degenerative joint disease: a retrospective cohort study

  2018cited by this paper
• PCSK9: From Basic Science Discoveries to Clinical Trials

  2018cited by this paper
• Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis

  2018cited by this paper
• PCSK9 inhibitors: clinical evidence and implementation

  2018cited by this paper
• Statins for Primary Prevention of Cardiovascular Disease.

  2017cited by this paper
• The Biopsychosocial Model of Low Back Pain and Patient-Centered Outcomes Following Lumbar Fusion.

  2017cited by this paper
• Mendelian Randomization.

  2017cited by this paper
• Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline

  2017cited by this paper
• MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data

  2017cited by this paper
• Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians.

  2017cited by this paper
• A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease

  2015cited by this paper
• Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

  2015cited by this paper
• Low back pain.

  2015cited by this paper
• Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta

  2015cited by this paper
• Cross-talk between LOX-1 and PCSK9 in vascular tissues.

  2015cited by this paper
• Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease.

  2015cited by this paper
• A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

  2014cited by this paper
• Costs Associated With Treatment of Chronic Low Back Pain: An Analysis of the UK General Practice Research Database

  2013cited by this paper
• A systematic review of the global prevalence of low back pain.

  2012cited by this paper
• The personal and national costs of early retirement because of spinal disorders: impacts on income, taxes, and government support payments.

  2012cited by this paper
• Statins alleviate experimental nerve injury‐induced neuropathic pain

  2011cited by this paper
• Atherosclerosis and disc degeneration/low-back pain--a systematic review.

  2009cited by this paper
• Lumbar disc disorders and low-back pain: socioeconomic factors and consequences.

  2006cited by this paper

• No citing papers are available for this paper.